Alkem Laboratories Limited — PPTs, 18-02-2026: Investor Presentation

Alkem Laboratories is making a significant move into the high-growth MedTech sector, projected to reach $870B globally by 2030. Alkem MedTech is prioritizing Musculoskeletal and Cardiovascular segments. Their Musculoskeletal division already shows strong traction with over 50% sequential implant growth and aims for 10% India market share in large joints in five years.

This strategic expansion leverages high entry barriers and continuous innovation in MedTech. A key step is acquiring a 51-55% stake in Occlutech Holding AG, a global leader in structural heart occluders (#2 in Europe, #3 worldwide). This acquisition offers a robust platform for global expansion, R&D, and an impressive product pipeline.

Alkem MedTech has signed an agreement to acquire Occlutech for €180.70 Mn (approx. Rs 1,951.6 Cr). Funded by internal accruals, the acquisition is expected to close by June 2026.

Occlutech reported net sales of €50 Mn (approx. Rs 540 Cr) for Jan-Dec 2025, achieving a 14% CAGR from 2021-25.

Alkem MedTech aims to be a substantial growth enabler for the broader Alkem Group, focusing on global presence, continuous innovation, and high-quality products in Orthopedics and Cardiovascular care.